Moleculin Biotech: Positive Clinical Trial Results and Strategic Developments Support Buy Rating

Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Moleculin Biotech (MBRX – Research Report) and keeping the price target at $4.00.

Jason McCarthy has given his Buy rating due to a combination of factors related to Moleculin Biotech’s recent clinical trial results and strategic developments. The company announced positive top-line data from its Phase 1b/2 study of Annamycin in soft tissue sarcoma lung metastases, showing a clinical benefit rate of 59.4% and notable improvements in overall survival, particularly in the Phase 2 portion of the study. These results suggest that Annamycin could be an effective treatment option, especially for patients with fewer prior therapies.
Additionally, despite a recent decline in stock price attributed to capital raising efforts, the ongoing enrollment for the Phase 3 MIRACLE study in relapsed/refractory acute myeloid leukemia is a significant step forward. The study’s progress in the US and planned expansion to the EU, along with an expected interim analysis in the second half of 2025, indicates a robust pipeline. The absence of cardiotoxicity in the trial data further strengthens the potential of Annamycin, supporting the Buy rating as the company advances its clinical programs.

MBRX’s price has also changed dramatically for the past six months – from $2.510 to $0.673, which is a -73.19% drop .